Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.10921
Peer-review started: August 9, 2021
First decision: August 29, 2021
Revised: September 6, 2021
Accepted: August 22, 2022
Article in press: August 22, 2022
Published online: October 26, 2022
Processing time: 437 Days and 18.4 Hours
There are little data on the epidemiological and clinical features of patients with adult ulcerative colitis (UC) in Italy.
This population-based observational study evaluated an entire population in a defined geographic area over an extended period of time. This is ideal to inform the natural history of disease and also to avoid selection biases associated with referral center cohort studies.
To describe the characteristics of patients at the time of UC diagnosis and to register the use of immunosuppressive treatments and biological drugs, surgeries, and malignancies after diagnosis of UC.
Consecutive patients with UC in ambulatory follow-up, at the time of the visit, were invited, after obtaining informed consent, to fill out a questionnaire concerning the natural history of their chronic disease object of the study.
Four hundred and forty-two patients were included in the sturdy. A high proportion of patients were treated with one or more biologics. 5-ASA remains the mainstay of UC treatment. Left-sided colitis is the most frequent location.
This is one of the first large-scale nationwide, observational studies to investigate the epidemiological characteristics of UC in Italy. Sardinia, a region geographically isolated from the European continent. This selected population is less likely to develop aggressive disease due to genetic or environmental factors.
Correct and objective mapping of the epidemiological and clinical characteristics of patients with UC, but in general with inflammatory bowel disease, cannot be separated from the presence of a national registry that compiles national data. It is desirable that this happens in Italy.
